220 related articles for article (PubMed ID: 21443470)
1. Biology of Cox-2: an application in cancer therapeutics.
Khan Z; Khan N; Tiwari RP; Sah NK; Prasad GB; Bisen PS
Curr Drug Targets; 2011 Jun; 12(7):1082-93. PubMed ID: 21443470
[TBL] [Abstract][Full Text] [Related]
2. [Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
Réti A
Magy Onkol; 2010 Dec; 54(4):377-81. PubMed ID: 21163769
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity.
Telliez A; Furman C; Pommery N; Hénichart JP
Anticancer Agents Med Chem; 2006 May; 6(3):187-208. PubMed ID: 16712448
[TBL] [Abstract][Full Text] [Related]
4. The pathophysiologic role of cyclo-oxygenases in the eye.
Radi ZA; Render JA
J Ocul Pharmacol Ther; 2008 Apr; 24(2):141-51. PubMed ID: 18355129
[TBL] [Abstract][Full Text] [Related]
5. Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018).
Mahboubi Rabbani SMI; Zarghi A
Expert Opin Ther Pat; 2019 Jun; 29(6):407-427. PubMed ID: 31132889
[TBL] [Abstract][Full Text] [Related]
6. DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention.
Gautam S; Roy S; Ansari MN; Saeedan AS; Saraf SA; Kaithwas G
Breast Cancer; 2017 Mar; 24(2):180-190. PubMed ID: 27558792
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 in cancer: A review.
Hashemi Goradel N; Najafi M; Salehi E; Farhood B; Mortezaee K
J Cell Physiol; 2019 May; 234(5):5683-5699. PubMed ID: 30341914
[TBL] [Abstract][Full Text] [Related]
8. Current directions for COX-2 inhibition in breast cancer.
Chow LW; Loo WT; Toi M
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S281-4. PubMed ID: 16507393
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro.
Andrews P; Zhao X; Allen J; Li F; Chang M
Cancer Chemother Pharmacol; 2008 Feb; 61(2):203-14. PubMed ID: 17447067
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2.
Ohtsu N; Takaoka K; Segawa E; Hashitani S; Noguchi K; Kishimoto H; Urade M
Oncol Rep; 2010 Jul; 24(1):31-6. PubMed ID: 20514441
[TBL] [Abstract][Full Text] [Related]
11. Alkaloids as Cyclooxygenase Inhibitors in Anticancer Drug Discovery.
Hashmi MA; Khan A; Farooq U; Khan S
Curr Protein Pept Sci; 2018; 19(3):292-301. PubMed ID: 28059042
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed.
Liu R; Xu KP; Tan GS
Eur J Pharmacol; 2015 Dec; 769():127-33. PubMed ID: 26548623
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2: a therapeutic target for prostate cancer.
Pruthi RS; Wallen EM
Clin Genitourin Cancer; 2005 Dec; 4(3):203-11. PubMed ID: 16425990
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
15. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways.
González-Périz A; Clària J
Curr Top Med Chem; 2007; 7(3):297-309. PubMed ID: 17305572
[TBL] [Abstract][Full Text] [Related]
16. The search for new COX-2 inhibitors: a review of 2002 - 2008 patents.
Ramalho TC; Rocha M; da Cunha EF; Freitas MP
Expert Opin Ther Pat; 2009 Sep; 19(9):1193-228. PubMed ID: 19563267
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2: a therapeutic target.
Turini ME; DuBois RN
Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
[TBL] [Abstract][Full Text] [Related]
18. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
Crew TE; Elder DJ; Paraskeva C
Carcinogenesis; 2000 Jan; 21(1):69-77. PubMed ID: 10607736
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels.
Shin YK; Park JS; Kim HS; Jun HJ; Kim GE; Suh CO; Yun YS; Pyo H
Cancer Res; 2005 Oct; 65(20):9501-9. PubMed ID: 16230415
[TBL] [Abstract][Full Text] [Related]
20. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.
Bernard MP; Bancos S; Sime PJ; Phipps RP
Curr Pharm Des; 2008; 14(21):2051-60. PubMed ID: 18691115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
